Company intelligence / Profile preview

Rio Biopharmaceuticals

Princeton, New Jersey, USAriobiopharma.com ↗

Ownership: Private
Development stage: Other

Overview

Rio Biopharmaceuticals has filed an ANDA with the FDA for a generic version of semaglutide injectable, targeting diabetes, and plans to launch both semaglutide and liraglutide injectables in the US. The company may qualify for 180 days of exclusivity upon launch of its generic semaglutide. No clinical trial results are reported as these are complex generics rather than novel drugs[1][10].

Therapeutic areas: Endocrinology
Modalities: Small moleculePeptides (notably GLP1 analogues like liraglutide and semaglutide)
Industry: Biotech

Drug pipeline

2 assets

Project M

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Oliva Therapeutics LLC – exclusive North American supply/distribution partnership for multi-product portfolio including initial launches from ~2024 onward[10]RBBL/Rio Biofarma Brasil Ltda – manufacturing collaboration/support[5]

Beyond the preview

Go deeper on Rio Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rio Biopharmaceuticals.

Explore the full profile